alpheon
biopartners gmbh - recombinant human interferon alfa-2a - hepatitas c, lėtinis - immunostimulants, - adult patients with histologically proven chronic hepatitis c who are positive for hepatitis c virus (hcv) antibodies or hcv rna and have elevated serum alanine aminotransferase (alt) without liver decompensation. the efficacy of interferon alfa-2a in the treatment of hepatitis c is enhanced when combined with ribavirin. alpheon should be given alone mainly in case of intolerance or contra-indication to ribavirin.
gepsam
vigifarma, uab - ademetioninas - milteliai ir tirpiklis injekciniam tirpalui - 500 mg/5 ml - ademetionine
fluconazole ibe
ibe pharma, uab - flukonazolas - infuzinis tirpalas - 2 mg/ml - fluconazole
thioctacid t
meda pharma gmbh & co. kg - tiokto rūgštis - injekcinis tirpalas - 600 mg/24 ml - tioctic acid
tavanic 250 mg plėvele dengtos tabletės
sanofi-aventis lietuva, uab, lietuva - levofloksacinas - plėvele dengtos tabletės - 250 mg - levofloxacin
livial
n.v. organon - tibolonas - tabletės - 2,5 mg - tibolone
tavanic
sanofi-aventis lietuva, uab - levofloksacinas - infuzinis tirpalas - 5 mg/ml - levofloxacin
tavanic
sanofi-aventis lietuva, uab - levofloksacinas - infuzinis tirpalas - 5 mg/ml - levofloxacin
pegasys
pharmaand gmbh - peginterferonas alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 ir 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. dėl sprendimo pradėti gydymą pediatrinių pacientų žr. skirsnius 4. 2, 4. 4 ir 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 ir 5. hepatito c viruso (hcv) genotipo specifinė veikla, žr. skirsnius 4. 2 ir 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. priimdamas sprendimą pradėti gydymą vaikystėje, svarbu, kad augimo slopinimas, sukeltas terapijos derinys. grįžtamumo augimo slopinimo yra neaiškus. sprendimas gydyti, turėtų būti priimtas kiekvienu atveju atskirai (žr. skyrių 4.
eltroxin
aspen pharma trading limited - levotiroksino natrio druska - tabletės - 100 µg - levothyroxine sodium